Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians

Journal of Emergency Medicine

Volumn 45, Issue 1, 2013, Pages 143-149

  Brem, Elizabeth ^a   Koyfman, Alex ^b   Foran, Mark ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Anticoagulants; Anticoagulation; Atrial fibrillation; Bleeding; Dabigatran; Embolism; Rivaroxaban; Stroke; Warfarin

Indexed keywords

AMINOCAPROIC ACID; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; DESMOPRESSIN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RIVAROXABAN; TRANEXAMIC ACID; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; EMERGENCY; FOOD AND DRUG ADMINISTRATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HEMOSTASIS; HUMAN; HYPERTENSION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBIN TIME; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; HEART ATRIUM FIBRILLATION; REVIEW; UNITED STATES; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG APPROVAL; EMERGENCIES; HEMORRHAGE; HUMANS; MORPHOLINES; STROKE; THIOPHENES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 84897353696     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2012.11.032     Document Type: Article

References (28)

1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
2. FDA Drug Safety Communication. Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm282724. htm. Accessed April 1, 2012.
3. Wann LS, Curtis AB, Ellenbogen KA, et al 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:144-50.
4. Guyatt G, Akl E, Crowther M., et al Executive summary: Antith-rombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S.
5. Patel MR, Mahaffey KW, Garg J, et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-91.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
7. Fuster V, Ryden L, Asinger RW, et al ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Circulation 2001;104:2118-50.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-6.
9. FDA appoves Pradaxa to prevent stroke in people with atrial fibrilation. 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm230241.htm. Accessed January 31, 2012.
10. Beasley B, Unger E, Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
11. Ganetsky M, Babu K, Salhanick S., Brown R, Boyer E. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011;7: 281-7.
12. Haviland Moore C., Snashall J, Boniface K., Scott J. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. Am J Emerg Med 2012;30:2082.e1-2.
13. Garber S, Sivakumar W, Schmidt R. Neurosurgical complications of direct thrombin inhibitors - catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012;116:1093-6.
14. Truumees E, Gaudu T, Dieterichs C., Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976) 2012;37: E863-5.
15. Fellows SE, Rosini JM, Curtis JA, Volz EG Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med 2012 May 15. [Epub ahead of print].
16. Lillo-Le Louët A, Wolf M, Soufir S, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation. Thromb Haemost 2012;108:583-5.
17. Mastrobuoni S, Robblee JA, Boodhwani M. Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. Interact Cardiovasc Thorac Surg 2012;15:299-300.
18. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. 2011. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm278646.htm. Accessed April 1, 2012.
19. Lassen MR, Ageno W, Borris LC, et al Rivaroxiban versus enoxaprin for thromboprophylaxsis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
20. Mega JL, Braunwald E, Wiviott SD, et al Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366: 9-19.
21. Granger CB, Alexander JH, McMurray JJ, et al Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-92.
22. Goldhaver SZ, Leizorovicz A, Kakkar A., et al Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77.
23. Kaatz S, Kouides PA, Garcia DA, et al Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(SUPPL. 1):S141-5.
24. Bauer K. Reversal of antithrombotic agents. Am J Hematol 2012; 87(SUPPL. 1):S119-26.
25. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
26. Crowther MA, Warkentin TE Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thrombo Haemost 2009;7(SUPPL. 1):107-10.
27. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-9.
28. Cotton BA, McCarthy JJ, Holcomb JB Acutely injured patients on dabigatran. N Engl J Med 2011;365:2039-40.